Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of MYK-224 with Itraconazole and Verapamil
NCT05304533Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BMS-986435 in hypertrophic cardiomyopathy (HCM), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 36 days and Area under the plasma concentration-time curve (AUC[0-T] and AUC[INF]) up to 36 days. Started Apr 2022; status: completed.
02
Drugs
BMS-986435
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT05304533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05304533.